Cost-effectiveness of carrier screening for cystic fibrosis in Australia

Journal of Cystic Fibrosis

Volumn 11, Issue 4, 2012, Pages 281-287

  Norman, Richard ^a   van Gool, Kees ^a   Hall, Jane ^a   Delatycki, Martin ^b   Massie, John ^b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Australia; Cost effectiveness; Cystic fibrosis; Economic evaluation; Screening

Indexed keywords

ARTICLE; AUSTRALIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DECISION TREE; DISEASE CARRIER; HUMAN; INFANT; MAJOR CLINICAL STUDY; PREGNANCY; PRENATAL SCREENING;

ADULT; AUSTRALIA; COHORT STUDIES; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; DERMATITIS, CONTACT; FAMILY HEALTH; FEMALE; GENETIC TESTING; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84862492005     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.02.007     Document Type: Article

References (14)

1. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245(4922):1066-1073.
2. Rommens J.M., Iannuzzi M.C., Kerem B., Drumm M.L., Melmer G., Dean M., et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245(4922):1059-1065.
3. Mennie M.E., Gilfillan A., Compton M., Curtis L., Liston W.A., Pullen I., et al. Prenatal screening for cystic fibrosis. Lancet 1992, 340(8813):214-216.
4. ACOG committee opinion no. 486: update on carrier screening for cystic fibrosis. Obstet Gynecol 2011, 117(4):1028-1031.
5. Massie J., Petrou V., Forbes R., Curnow L., Ioannou L., Dusart D., et al. Population-based carrier screening for cystic fibrosis in Victoria: the first three years experience. Aust N Z J Obstet Gynaecol 2009, 49(5):484-489.
6. Radhakrishnan M., van Gool K., Hall J., Delatycki M., Massie J. Economic evaluation of cystic fibrosis screening: a review of the literature. Health Policy 2008, 85(2):133-147.
7. Wildhagen M.F., Hilderink H.B., Verzijl J.G., Verheij J.B., Kooij L., Tijmstra T., et al. Costs, effects, and savings of screening for cystic fibrosis gene carriers. J Epidemiol Community Health 1998, 52(7):459-467.
8. Nielsen R., Gyrd-Hansen D. Prenatal screening for cystic fibrosis: an economic analysis. Health Econ 2002.
9. Maxwell S., Brameld K., Youngs L., Geelhoed E., O'Leary P. Informing policy for the Australian context - costs, outcomes and cost savings of prenatal carrier screening for cystic fibrosis. Aust N Z J Obstet Gynaecol 2010, 50(1):51-59.
10. Chambers G.M., Ho M.T., Sullivan E.A. Assisted reproductive technology treatment costs of a live birth: an age-stratified cost-outcome study of treatment in Australia. Med J Aust 2006, 184(4):155-158.
11. Van Gool K., Norman R., Delatycki M., Massie J., Hall J. Cystic fibrosis: a study of cost of care by age and severity CHERE working paper 2011/1 2011.
12. Department of Health and Ageing Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.2) Canberra. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacguidelines-index.
13. Williams A., Cookson R. Equity in Health. Handbook of health economics 2000, Elsevier, Amsterdam. A.J. Culyer, J.P. Newhouse (Eds.).
14. Norman R., Haas M., Wilcken B. International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions. Health Policy 2009, 89(3):252-260.